---
schema_version: "secwatch.filing_event.v1"
accession: "0001000694-25-000024"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T02:51:19.231999+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Novavax Q1 revenue $667M, net income $519M; raises FY guidance to $975M-$1.025B

## Summary
- Total revenue $667M vs $94M YoY; net income $519M vs net loss $148M.
- Raises full-year adjusted total revenue framework to $975M-$1,025M (from $300-$350M).
- FDA BLA review on track; approval triggers $175M milestone from Sanofi; MAs to Sanofi by Q4 2025.
- Strengthened Takeda partnership: $20M upfront, annual milestones plus royalties on Japan sales.
- SHIELD-Utah: Nuvaxovid recipients had ~39% fewer reactogenicity symptoms vs mRNA vaccine.

## SEC filing metadata
- accession: 0001000694-25-000024
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000100069425000024/0001000694-25-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000100069425000024/nvax-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001000694-25-000024
- JSON: https://secwatch.observer/filing/0001000694-25-000024.json
- Plain text: https://secwatch.observer/filing/0001000694-25-000024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.